title: Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.
abstract: OBJECTIVE
  Secretory leukocyte protease inhibitor (SLPI) is amplified in serous ovarian cancer. We have dissected its function, showing it is a survival factor for ovarian cancer and promotes tumorigenesis and paclitaxel-resistance. We hypothesized that the protease inhibitory function was responsible for modulating SLPI's invasive capacity.
  
  
  METHODS
  Stable HEYA8 ovarian cancer transfectants expressing vector, wild type SLPI, and protease inhibitor null (F-)SLPI were examined in vitro and in xenografts. Invasion, enzyme activity, and MMP production and function assays were applied. SLPI and MMP immunoexpression was graded on tissue microarray and clinical samples. Statistical comparisons used unpaired t test and ANOVA, where appropriate.
  
  
  RESULTS
  SLPI and F-SLPI cells caused greater parenchymal and peritoneal dissemination over control cells in xenografts and invasion assays (p<0.001). MMP-9 protease activity was increased in SLPI and F-SLPI cells over control. SLPI, but not F-SLPI, inhibited plasmin activity, necessary for MMP-9 activation and release, and inhibited activation of MMP-9. However, paradoxically, both induced quantitative MMP-9 transcription (p<0.05) and protein (p<0.008), yielding an increased net MMP-9 activity in the face of plasmin inhibition. SLPI and MMP-9 expression were strongly correlated in serous ovarian cancers (r(2)=0.986) and a set of ovarian cancers (p<0.02). SLPI expression was greater in serous than endometrioid ovarian cancers (p=0.04).
  
  
  CONCLUSIONS
  SLPI stimulates ovarian cancer invasion, modulated in part by its serine protease inhibitory activity attenuating MMP-9 release. However, SLPI induction of MMP-9, independent of protease inhibition activity, is greater yielding a net pro-invasive behavior. These findings further support SLPI as a molecular target for ovarian cancer.
authors.affiliation: Molecular Signaling Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
authors.forename: Ebony
authors.initials: E
authors.lastname: Hoskins
authors.forename: Jaime
authors.initials: J
authors.lastname: Rodriguez-Canales
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hewitt
authors.forename: Wafic
authors.initials: W
authors.lastname: Elmasri
authors.forename: Jasmine
authors.initials: J
authors.lastname: Han
authors.forename: Shing
authors.initials: S
authors.lastname: Han
authors.forename: Ben
authors.initials: B
authors.lastname: Davidson
authors.forename: Elise C
authors.initials: EC
authors.lastname: Kohn
mesh_terms: D018284:Cystadenocarcinoma, Serous / Q000201:enzymology / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005260:Female; D005341:Fibrinolysin / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000201:enzymology / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic; D014162:Transfection; D015854:Up-Regulation
chemical_list: C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D005341:Fibrinolysin; D020780:Matrix Metalloproteinase 9